Open AccessLow-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results
Author(s) -
Alexander Popov,
Günter Henze,
Yu. V. Rumyantseva,
О. И. Быданов,
Mikhail Belevtsev,
Tatiana Verzhbitskaya,
Elena Boyakova,
Liudmila Movchan,
Grigory Tsaur,
Maria Fadeeva,
Svetlana Lagoyko,
Liudmila Zharikova,
N. V. Myakova,
Dmitry Litvinov,
Olga Khlebnikova,
Olga Streneva,
Elena Stolyarova,
Natalia Ponomareva,
Galiovichkova,
Larisa Fechina,
О. В. Алейникова,
Alexander Karachunskiy
Publication year - 2022
Publication title -
voprosy gematologii/onkologii i immunopatologii v pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 3
eISSN - 2414-9314
pISSN - 1726-1708
DOI - 10.24287/1726-1708-2022-21-2-95-104
Subject(s) - medicine , minimal residual disease , cyclophosphamide , methotrexate , hematology , clinical trial , oncology , daunorubicin , leukemia , pediatrics , chemotherapy